Cargando…
Interventions to Increase Leukocyte Testing during Treatment with Dimethyl Fumarate
Dimethyl fumarate (DMF), a treatment for multiple sclerosis, may cause leukopenia and infection. Accordingly, periodic white blood cell (WBC) monitoring is recommended. We sought to evaluate the US Department of Veteran Affairs’ safety program which provides facilities with a list of patients prescr...
Autores principales: | Heidenreich, Paul A., Lin, Shoutzu, Gholami, Parisa, Moore, Von R., Burk, Muriel L., Glassman, Peter A., Cunningham, Francesca E., Sahay, Anju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507868/ https://www.ncbi.nlm.nih.gov/pubmed/34639610 http://dx.doi.org/10.3390/ijerph181910312 |
Ejemplares similares
-
How successful was the use of a community of practice for the implementation of evidence-based practices for heart failure within the United States Department of Veterans Affairs: Insights from a formative evaluation
por: Sahay, Anju, et al.
Publicado: (2022) -
Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients
por: Goldman, Myla D., et al.
Publicado: (2020) -
Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017) -
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016) -
Effects of dimethyl fumarate on neuroprotection and immunomodulation
por: Albrecht, Philipp, et al.
Publicado: (2012)